O'PKANING MAYDA HUJAYRALI SARATONIDA BIRINCHI QATOR KIMYOTERAPIYANING KLINIK SAMARADORLIGI VA TOKSIKLIGI
Keywords:
o'pkaning mayda hujayrali saratoni, birinchi qator kimyoterapiya, sisplatin, etopozid, toksiklik, RECIST, CTCAE.Abstract
Ushbu tadqiqotda o'pkaning mayda hujayrali saratoni (SCLC) bilan kasallangan bemorlarda birinchi qator kimyoterapiyaning klinik samaradorligi va toksikligi baholandi. Tadqiqotga birinchi qator davolash olgan bemorlar jalb qilindi. Davolash samaradorligi RECIST 1.1 mezonlari asosida, toksiklik esa CTCAE 5.0 klassifikatsiyasi bo'yicha baholandi. Tadqiqot natijalari birinchi qator kimyoterapiya kasallik nazoratini ta'minlashda yuqori samaradorlikka ega ekanligini ko'rsatdi. Asosiy nojo'ya ta'sirlar gematologik toksiklik va gastrointestinal buzilishlar bo'lib, aksariyat hollarda konservativ davolash yordamida bartaraf etildi.
References
European Organisation for Research and Treatment of Cancer. RECIST Guideline Version 1.1. 2009.
European Society for Medical Oncology. Small-cell lung cancer: ESMO Clinical Practice Guideline. 2023.
Horn L., et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine. 2018;379:2220–2229.
Kalemkerian G. P., et al. Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network. 2023.
National Cancer Institute. CTCAE Version 5.0. 2017.
National Comprehensive Cancer Network. Small Cell Lung Cancer. NCCN Clinical Practice Guidelines in Oncology. Version 2025.
Paz-Ares L., et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN). The Lancet. 2019;394:1929–1939.
Rudin C. M., et al. Small-cell lung cancer. Nature Reviews Disease Primers. 2021;7:3.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles published in IQRO — Scientific Methodological Journal are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Authors retain copyright and grant the journal the right of first publication.
Users may read, download, copy, distribute, print, search, or link to the full texts of articles, provided that the original authors and the journal are properly cited.
Published materials may be used, distributed, and reproduced in any medium, provided that the original work is properly cited.



Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo